Kunlun Capital
Seed–Late Stage
What they invest in
from 1 of 1 portfolio companiesBiotech ×1Deep Tech ×1Healthtech ×1
Investments · 1 tracked
founders shown can be your intro pathEdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalBioTrack Capital+2 more
Frequently asked questions
- What stage does Kunlun Capital invest at?
- Kunlun Capital invests at the Seed, Late Stage stages.
Similar investors
83North is a global venture capital firm that invests in and helps entrepreneurs build large, category-defining companies, backing startups across multiple stages and sectors.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.
AirTree Ventures runs Pathfinders, a free four-week in-person program in Sydney for young builders (high-school graduates up to age 23) to work on a real product, access the AirTree team and founders, and build a peer network.